Suzanne Cosgrove

Become a sponsor »

Suzanne Cosgrove Occupation Contributing Editor Employer John J. Lothian & Company, Inc. Location Chicago Twitter @srcosgrove LinkedIn Profile Website www.johnlothiannews.com Suzanne Cosgrove is a journalist, adjunct professor and communications professional who is an editor at John Lothian News. Formerly, she was director of corporate communications at Cboe Global Markets. Before joining the Cboe, she was a freelance editor, writer and educator. She was a writer and editor for Cosgrove Communications and a contributing writer with Market News International. She is an adjunct professor of journalism at the Medill School of Journalism at Northwestern University She is a member of the Tribune un-linked group. Background Cosgrove worked as a financial editor at the Chicago Tribune from 2000 through 2009. She has been an adjunct professor at Northwestern University’s Medill School of Journalism and freelanced as an editor and writer on a variety of topics, including finance, markets and real estate. Also previously, she served as Market News International’s Chicago bureau chief and covered the Chicago futures markets, banking and economics for Knight-Ridder Financial News. Education She holds a master’s degree in journalism from Medill and a bachelor’s degree from Loyola University/Mundelein College. References

JLN News Feed The Spread: Make Way for the SA-CCR Chris Hehmeyer – Bitcoin, Bakkt and Beyond VIX clues show how stock investors underpriced the risk of the coronavirus pandemic; The Booming Short-Volatility Bet That Lost 46% in a Single Month Dan Draper Sponsor News [TSETSE to launch Investor Transcript Service] CME Group Reports All-Time High ADV for March and First-Quarter 2020 [JPX,TSE,OSETrading Overview in FY2019 & March 2020] DTCC Adds Two Industry Veterans to Board of Directors [JPX,TSE,OSE,JPX-R,JSCC,TOCOMJPX response to spread of novel coronavirus] We visit more than 100 websites daily for financial news (Would YOU do that?). Read the John Lothian Newsletter. FREE 90 day trial